Carol Greve-Philips

Carol Greve-Philips is a seasoned biotechnology business development professional with extensive experience across various leadership roles in the industry. Currently serving as Chief Business Officer at Navega Therapeutics since February 2024, Carol has also operated as a Senior Biotechnology Business Development Executive through an independent consultancy since January 2017. Previous positions include Senior Vice President of Business Development and Strategy at Spark Therapeutics LLC and Chief Business Officer at Pronota, where strategic partnerships and business development initiatives were pivotal. Notably, during tenure at Genzyme Corporation, Carol held multiple senior roles, contributing to high-value transactions and developing innovative business strategies. Early career experience includes roles at Chemsyn Science Labs and Amersham Corporation. Carol holds a Bachelor of Science degree in Biology from the University of Massachusetts Amherst.